19 - CLINICAL TRIALS: About a revolution

Specialising in the conduct of clinical trials in a patient’s home through the deployment of healthcare professionals (Clinical solutions) and recently, by adding a whole suite of digital technology (eClinical solutions), their “Home Trial Support” service allows patients to participate in trials more conveniently than just visiting a hospital.

Running trials in a patient’s community solves two significant challenges to successful clinical trials: patient recruitment and patient retention. Many trials benefit from Home Trial Support and MRN has trailblazed by delivering many ‘difficult’ trials; those with large numbers of countries, where drugs must be infused or injected by a nurse and/or those with challenging paediatric or rare-disease patient populations – often difficult to recruit into studies due to geographical location. MRN’s unparalleled innovative and creative in-home visit designs, combining clinical and digital decentralised elements, enhances the execution of clinical trials, making them more flexible, more efficient and with improved data quality.

MRN’s position, as an innovative, market-leading, organisation has resulted in them being awarded a prestigious 2022 Queen’s Award for Enterprise - Excellence in International Trade. MRN is headquartered in Milton Keynes with offices in the US, Spain, Germany and Japan and a global network of healthcare professionals allowing them to operate in over 50 countries.

Graham Wylie, Founder and CEO, commented, “We are honoured to receive the prestigious Queen’s Award as it recognises the incredible growth of our business and the dedication of our employees, global network of healthcare professionals, vendors, and partners. MRN is dedicated to making healthcare more accessible for patients, clinical trials less burdensome for families and helping bring new medicines to people faster.”

Decentralised clinical trials were instrumental in rescuing many clinical trials through the Covid 19 pandemic. MRN, already one of the UK’s fastest growing healthcare businesses, saw the impact of the pandemic on global clinical research first hand. As the pandemic hit, the clinical trial industry urgently needed to pivot many trials into the decentralised model, away from hospitals/research centres – MRN stepped up and delivered.

Despite all the issues COVID-19 still causes, MRN have continued to deliver for the expanding customer base. This is due to MRN’s systems, processes and, most of all, the dedication and hard work of their passionate employees and allies who believe in the decentralised trial model as the future of clinical research.

Stuart Redding, COO, explained: “We will continue to drive the decentralised clinical trial market by continuing to innovate, expand our geographical reach, enhance our solutions with digital technology and expanding our portfolio of services organically and through an active acquisition policy. We do this to deliver clinical trials to patients in their own communities around the globe efficiently. This award is a further validation of our position as the catalysts of decentralised clinical trials, designing and scaling trials quickly and efficiently, bringing medicines to market faster.”

See how the elements in MRNs periodic table can assist you at themrn.io